Brought to you by 
Tmunity's Series A brings in $100mm; $35mm added
20 Apr 2018
Executive Summary
Tmunity Therapeutics Inc. (T-cell therapies for cancer, infectious diseases, and autoimmune conditions) raised $100mm through its Series A round. Seed investors University of Pennsylvania and Lilly Asia Ventures were joined by new investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc., and Be The Match BioTherapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tmunity's Series A brings in $100mm; $35mm added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice